Reperfusion injury is the damage to tissues caused when blood supply returns to the tissue after a period of ischemia or lack of oxygen (anoxia, hypoxia). It influences the patient’s outcome after myocardial infarction, stroke, cardiovascular surgery, and organ transplantation. The treatments available for reperfusion injury are therapeutic hypothermia, hydrogen sulfide treatment, cyclosporin, stem cell therapy and metformin. Radikal Therapeutics Inc. is in the process of developing R-190 as an intravenous formulation for the treatment of limb ischemia reperfusion injury. The drug candidate is being developed as a small molecule which acts as a nitric oxide donors and reactive oxygen species inhibitor. Some of the companies having a pipeline of reperfusion injury include Catalyst Biosciences Inc., MIFCOR Inc. and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.